MET and gastric cancer: In particular, a subset of RTK alterations including human epithelial growth factor receptor-2 (HER-2), mesenchymal epithelial transition factor receptor (MET), and fibroblast growth factor receptor 2 (FGFR2) are found in a subset of gastric cancer patients, and are associated with advanced tumor condition, metastasis, and poor prognosis of gastric cancer patients [9,10].